ELEVATED SERUM CHROMOGRANIN A CONCENTRATIONS IN SMALL-CELL LUNG-CARCINOMA
ELEVATED SERUM CHROMOGRANIN A CONCENTRATIONS IN SMALL-CELL LUNG-CARCINOMA
复制标题
DOI：
10.7326/0003-4819-105-5-698
复制
发表时间：
1986-11-01
影响因子：
39.2
通讯作者：
DEFTOS, LJ
中科院分区：
文献类型：
--
作者：
SOBOL, RE;OCONNOR, DT;DEFTOS, LJ
采用放射免疫法测定小细胞肺癌患者血清嗜铬粒蛋白A浓度，并与健康成人、非小细胞肺癌和慢性阻塞性肺疾病患者血清嗜铬粒蛋白A浓度进行比较。平均值（.+-. SE）水平在小细胞肺癌组（815 ± 0.01）显著高于对照组（P < 0.02）。290 ng/mL，n = 46）比正常对照组（123 . ±. 6 ng/mL，n = 20）或慢性阻塞性肺疾病患者（169 . ±. 18 ng/mL，n = 39）、肺腺癌（180 . ±. 22，ng/mL，n = 62），大细胞肺癌（183 . ±. 23 ng/mL，n = 18）或肺表皮样癌（203 . ±. 37 ng/mL，n = 78）。在广泛期小细胞肺癌中的平均浓度（1155 ± 0.001）。449 ng/mL，n = 29）显著高于（p = 0.026）局限性疾病（234 . ±. 56 ng/mL，n = 17）。53%的局限性和72%的广泛性疾病患者血清嗜铬粒蛋白A值升高。最初被归类为非小细胞肺癌的嗜铬粒蛋白A水平升高的四名患者随后被发现有混合小细胞和非小细胞肿瘤。血清嗜铬粒蛋白A浓度可能是小细胞肺癌疾病活动性的有用标志。
Serum chromogranin A concentrations measured by radioimmunoassay in patients with small-cell lung carcinoma were compared with values from healthy adults and paitents with non-small-cell lung carcinoma or chronic obstructive pulmonary disease. The mean (.+-. SE) level was significantly higher (p < 0.02) in patients with small-cell lung carcinoma (815 .+-. 290 ng/mL, n = 46) than in normal controls (123 .+-. 6 ng/mL, n = 20) or patients with chronic obstructive pulmonary disease (169 .+-. 18 ng/mL, n = 39), lung adenocarcinoma (180 .+-. 22, ng/mL, n = 62), large-cell lung carcinoma (183 .+-. 23 ng/mL, n = 18), or lung epidermoid carcinoma (203 .+-. 37 ng/mL, n = 78). The mean concentration in extensive-stage small-cell lung carcinoma (1155 .+-. 449 ng/mL, n = 29) was significantly greater (p = 0.026) than in limited disease (234 .+-. 56 ng/mL, n = 17). Elevated serum chromogranin A values were seen in 53% of patients with limited and 72% with extensive disease. Four patients originally classified as having non-small-cell lung carcinomas with raised chromogranin A levles were subsequently found to have mixed small-cell and non-small-cell tumors. Serum chromogranin A concentrations may be a useful marker of small-cell lung carcinoma disease activity.